This phase III trial compares low dose whole lung radiation therapy to best supportive care plus physicians choice in treating patients with COVID-19 infection. Low dose whole lung radiation therapy may work better than the current best supportive care and physician's choice in improving patients' clinical status, the radiographic appearance of their lungs, or their laboratory blood tests.
PRIMARY OBJECTIVE:
I. Intubation-free survival (IFS) and (2) time to clinical recovery (TTCR) based on weaning
off supplementary oxygenation or hospital discharge in COVID 19 patients.
SECONDARY OBJECTIVES:
I. To investigate (1) other clinical, (2) radiographic, (3) serologic markers, and (4) immune
marker response to best supportive care plus provider's choice of pharmaceutical treatment
either with or without whole-lung LD-RT
II. Secondary clinical improvements will look at time to hospital discharge, prevention of
ICU admissions, and overall survival.
OUTLINE: Patients are blindly randomized to 1 of 2 arms.
ARM I: Patients receive best supportive care plus physician choice of treatment
ARM II: Patients receive best supportive care plus LDRT (experimental arm).
After completion of study, patients are followed up for 14 days.
Other: Best Practice
Receive standard of care
Other Name: Array
Radiation: Low Dose Radiation Therapy
Undergo LDRT
Other Name: Low Dose Radiation
Inclusion Criteria:
- Be age 50 or over; Not pregnant (will undergo pregnancy testing if below age 55);
- Have had a positive PCR-based test confirming the diagnosis of COVID-19 within 5 days
(+/-2 day)of study enrollment*
- Have had clinical signs of severe acute respiratory syndrome or pneumonia (ie.
dyspnea, cough,fever) that primary team feels like patient needs rescuing with
LD-RT.**
- Have visible bilateral consolidations/ground glass opacities on chest imaging
- Require supplemental oxygen at the time of enrollment, defined by inability to wean
from supplemental oxygen within 24 hours prior to enrollment.
- Not require intubation within 12 hours of randomization (ie, not screen fail).
Intubation after enrollment but within 12 hours of randomization will be defined as a
screen failure for both the LD-RT and control cohorts.
- Be enrolled within 5 days (+/- 2) of first hospitalization for COVID-19. Prior
hospitalization for COVID-19 will be an exclusion criteria (prior ED visits are
permissible).
- Willingness and ability of the subject to comply with scheduled visits,
protocol-specified laboratory tests, other study procedures, and study restrictions
- Evidence of a signed informed consent/assent indicating that the subject is aware of
the infectious nature of the disease and has been informed of the procedures to be
followed, potential risks and discomforts, potential benefits, and other pertinent
aspects of study participation
Exclusion Criteria:
- Pregnant and/or planned to be pregnant within in next 6 months
- Age 49 or younger at time of enrollment
- Prior inpatient hospitalization for COVID-19 (prior emergency department [ED] visits
are not an exclusion criteria)
- Prior enrollment on a separate COVID-19-related therapeutric trial (subsequent
co-enrollment is permitted for patinets randomized to the control arm).
- Notably, concurrent use of COVID-directed therapies is no longer an exclusion criteria
for this trial. This includes azithromycin, dexamethasone, remdesevir, convalescent
plasma, or any other COVIDdirected drug therapy.
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, United States
Investigator: Allyson Anderson
Contact: 404-251-2854
allyson.anderson@emory.edu
Investigator:
Mohammad K Khan, MD, PhD
404-778-3473
drkhurram2000@gmail.com
Clayton B Hess, MD, MPH
404-616-3947
cbhess@emory.edu
Mohammad K Khan, MD, PhD, Principal Investigator
Emory University Hospital/Winship Cancer Institute